PHARMACOKINETICS AND SAFETY OF ELAFIBRANOR IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION

被引：0
|
作者：
Noel, Benoit [1 ]
Vargas, Dawn [2 ]
Georges-Coty, Anne [1 ]
Roudot, Alice [1 ]
Roux, Olivier [3 ]
Magrez, David [1 ]
Wyatt, David [4 ]
Birman, Pascal [1 ]
Addy, Carol [1 ,5 ]
机构：
[1] Genfit SA, Loos, France
[2] Genfit CORP, Loos, France
[3] It&m Stats, Neuilly Sur Seine, France
[4] Syneos Hlth, Morrisville, NC USA
[5] Genfit SA, Clin Dev, Loos, France
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1287
引用
收藏
页码：772A / 773A
页数：2
相关论文
共 50 条
  • [31] The pharmacokinetics of lamivudine in patients with impaired hepatic function
    Johnson, MA
    Horak, J
    Breuel, P
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (04) : 363 - 366
  • [32] The pharmacokinetics of lamivudine in patients with impaired hepatic function
    M. A. Johnson
    J. Horak
    P. Breuel
    European Journal of Clinical Pharmacology, 1998, 54 : 363 - 366
  • [33] Pharmacokinetics, Safety, and Tolerability of Maraviroc in HIV-Negative Subjects with Impaired Renal Function
    Vourvahis, Manoli
    Fang, Juanzhi
    Checchio, Tina
    Milton, Ashley
    Weatherley, Barry
    McFadyen, Lynn
    Heera, Jayvant
    HIV CLINICAL TRIALS, 2013, 14 (03): : 99 - 109
  • [34] Pharmacokinetics, pharmacodynamics, and safety of ciprofol emulsion in Chinese subjects with normal or impaired renal function
    Tao, Jun
    Liu, Shuaibing
    Zhao, Ying Ying
    Qi, Lei
    Yan, Pangke
    Wu, Nan
    Liu, Xiao
    Liu, Dongwei
    Tian, Xin
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [35] Comparative pharmacokinetics of multiple-dose candesartan in subjects with and without impaired hepatic function.
    Dingemanse, J
    Kleinbloesem, CH
    Hoogkamer, JFW
    Ouwerkerk, M
    Hogemann, A
    Nokhodian, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII61 - PII61
  • [36] Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function
    Zhou, XJ
    Myers, M
    Chao, G
    Dubuc, G
    Brown, N
    JOURNAL OF HEPATOLOGY, 2004, 40 : 134 - 134
  • [37] PHARMACOKINETICS AND SAFETY OF BELAPECTIN, A CANDIDATE DRUG FOR NASH CIRRHOSIS, IN SUBJECTS WITH NORMAL HEPATIC FUNCTION AND SUBJECTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT
    Lowe, Ezra
    Schoenfeld, Steven
    Lawitz, Eric
    Harrison, Stephen A.
    Kayali, Zeid
    Boudes, Pol
    HEPATOLOGY, 2023, 78 : S1432 - S1432
  • [38] Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment
    Hossain, Mohammad
    Tiffany, Courtney
    Tao, Yu
    Barth, Aline
    Marbury, Thomas C.
    Preston, Richard A.
    Dumont, Etienne
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (06): : 588 - 597
  • [39] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SELADELPAR IN SUBJECTS WITH HEPATIC IMPAIRMENT
    Mao, Z.
    Martin, Robert
    Steinberg, Alexandra
    Rohane, Patricia
    Nguyen, Jaidyn
    Standen, Mary
    Boudes, Pol
    GASTROENTEROLOGY, 2019, 156 (06) : S1320 - S1320
  • [40] Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment
    Xin, Yan
    Kawashima, Jun
    Weng, Winnie
    Kwan, Ellen
    Tarnowski, Thomas
    Silverman, Jeffrey A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (04): : 522 - 532
12345